Upstream Bio, Inc. (NASDAQ:UPB) Given Average Rating of “Moderate Buy” by Analysts

Upstream Bio, Inc. (NASDAQ:UPB) has been given an average rating of “Moderate Buy” by the five ratings firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $45.25.

Several equities research analysts recently weighed in on UPB shares. Evercore began coverage on Upstream Bio in a research report on Tuesday, November 18th. They set an “outperform” rating and a $40.00 price target on the stock. Mizuho raised shares of Upstream Bio to a “strong-buy” rating in a research report on Thursday, December 18th. Lifesci Capital assumed coverage on shares of Upstream Bio in a research report on Tuesday, December 2nd. They set an “outperform” rating and a $43.00 price target for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Upstream Bio in a research note on Wednesday, January 21st.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in UPB. Renaissance Technologies LLC purchased a new position in Upstream Bio during the fourth quarter valued at $445,000. New York State Common Retirement Fund raised its position in shares of Upstream Bio by 85.7% in the 4th quarter. New York State Common Retirement Fund now owns 11,700 shares of the company’s stock worth $318,000 after purchasing an additional 5,400 shares during the last quarter. Alps Advisors Inc. grew its position in Upstream Bio by 70.9% during the 4th quarter. Alps Advisors Inc. now owns 44,376 shares of the company’s stock valued at $1,205,000 after purchasing an additional 18,414 shares during the last quarter. Swiss National Bank purchased a new stake in Upstream Bio during the 4th quarter valued at about $722,000. Finally, Nuveen LLC increased its stake in Upstream Bio by 12.4% during the 4th quarter. Nuveen LLC now owns 78,568 shares of the company’s stock valued at $2,133,000 after purchasing an additional 8,686 shares in the last quarter.

Key Headlines Impacting Upstream Bio

Here are the key news stories impacting Upstream Bio this week:

• Positive Sentiment: Phase 2 top-line success — Upstream said verekitug produced statistically significant and clinically meaningful reductions in annualized asthma exacerbation rate (AAER) at two dosing regimens (100 mg q12 and 400 mg q24), supporting proof-of-concept for the program. Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug
• Positive Sentiment: Strong efficacy signal reported — Company claims large reduction in asthma attacks (reported ~56% reduction in attacks for an effective dose), evidence that could support further development if dose/regimen is optimized. Upstream Bio Shows Asthma Drug Cuts Attacks By 56%, Stock Reacts
• Neutral Sentiment: Company provided a webcast and top-line presentation — management is giving investors a first look; full data and subgroup/readout timing will be critical next catalysts. Upstream Bio Reports Positive Phase 2 Verekitug Asthma Results
• Negative Sentiment: Market punished the stock because the benefits were dose-specific and not across all arms — headlines framed the outcome as “mixed” or “the wrong dose,” creating uncertainty about the optimal regimen, regulatory path and commercial positioning. Upstream Bio crashes after asthma drug succeeds — with the wrong dose
• Negative Sentiment: Heavy selling and profit-taking after the initial pop — high volume and headline-driven selling pushed the stock lower despite the positive headline metrics, reflecting investor caution until full data are released. Upstream Bio stock tumbles after mixed Phase 2 asthma trial results

Upstream Bio Stock Performance

Upstream Bio stock opened at $12.80 on Friday. Upstream Bio has a fifty-two week low of $5.14 and a fifty-two week high of $33.68. The stock’s 50 day simple moving average is $28.63 and its two-hundred day simple moving average is $23.22. The stock has a market cap of $691.71 million, a price-to-earnings ratio of -6.81 and a beta of 1.90.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.